Immune checkpoint inhibition alters the inflammatory cell composition of human coronary artery atherosclerosis

Immune checkpoint inhibition (ICI) has emerged as a promising new approach to treat malignancy. Such therapies can result in autoimmune-related complications such as myocarditis and hepatitis. The impact of ICI on sites of preexisting chronic inflammation has been less clear. Atherosclerosis is a chronic vascular disease with a significant inflammatory component. To determine the effect of ICI on the inflammatory infiltrate in coronary artery...